Fujifilm Advances Healthcare with Comprehensive AI-Driven Gastrointestinal Endoscopy Solution for Early Detection Accuracy

Bangkok, 7 December 2023 – Fujifilm, a leading provider of total healthcare solutions, is intensifying its efforts to offer the healthcare sector a comprehensive range of AI-powered medical solutions. The goal is to empower medical professionals globally, enabling accurate diagnoses and early disease detection for patients. At the Asia Pacific Digestive Week 2023 (APDW 2023) in Bangkok, the company showcased cutting-edge medical products, including Fujifilm’s advanced AI solution for endoscopy, known as “CAD EYE.” This innovative technology is poised to advance medical diagnostics, particularly in the field of gastrointestinal cancer. In addition to this groundbreaking technology, Fujifilm disclosed its plans to introduce new AI solution to assist diagnosis in stomach and oesophagus in 2024 with advanced medical solutions aimed at preventing avoidable illnesses and casualties. This strategic move underscores Fujifilm’s dedication to innovating for a healthier world.

Mr. Masataka Akiyama, Director, Corporate Vice President and General Manager, Medical Systems Business Division of FUJIFILM Corporation, outlines the evolution of Fujifilm's journey in developing Total Healthcare Solutions, saying, “Healthcare has become the largest sector for FUJIFILM Corporation, with the Medical Systems Business Division serving as its core.  Leveraging Fujifilm's proprietary image processing technologies, AI technologies and other expertise, the Medical Systems Business offers a broad spectrum of medical devices and services, encompassing X-ray diagnostic systems, endoscopy, diagnostic ultrasound systems, in-vitro diagnostics (IVD), and healthcare IT solutions. The addition of FUJIFILM Healthcare Corporation in 2021 has further propelled the growth of the Medical Systems Business Division, leading to an expansion of the product lineup to now include CT and MRI systems.” 

Mr. Masataka Akiyama also highlights the collaborative synergy within the Fujifilm Group, emphasizing the integral contributions of Fujifilm’s endoscopy system and FUJIFILM Healthcare’s diagnostic ultrasound system ARIETTA850. This concerted effort is geared towards expediting the development and diversification of product offerings within a globally integrated sales network. “The combined strengths of these organizations bolster our capacity to present comprehensive solutions from our extensive portfolio,” he explains.   

Recent data indicates that in 2021, 15 million individuals aged 50 and above in Thailand face a heightened risk of colorectal cancer. These alarming statistics highlight the importance of improving accuracy in diagnoses and ensuring timely treatment for gastrointestinal diseases.  

In response to the crucial need for precise early detection, Fujifilm introduced its AI solution for endoscopy, "CAD EYE". The solution serves as an empowering tool harnessing Artificial Intelligence technology, aiding gastroenterologists in the early detection and characterization of abnormal lesion in the gastrointestinal tract. Looking ahead to 2024, Fujifilm plans to unveil the new product “CAD EYE Upper GI “the new version of CAD EYE for upper GI in Thailand. This new version, tailored for diagnosing issues in the stomach and oesophagus, aims to assist in endoscopic diagnosis in the Upper Gastrointestinal tract, further expanding Fujifilm's endoscopy portfolio. 

Mr. Tatsuhiko Saeki, General Manager of Endoscopy, FUJIFILM Corporation talks about the CAD EYE solution, "With the introduction of our groundbreaking AI technology for gastrointestinal endoscopy, we advance medical diagnostics significantly. We have been a forerunner in worldwide for the AI diagnostic technology for assisting detection and characterization of lesion in colon, and this is the second chapter. This endoscopic diagnosis support software detects areas suspected of gastric neoplastic lesions and oesophageal squamous cell carcinoma in real time. When this software detects an area suspected of being a lesion, it displays a frame (detection box) surrounding the target area and emits a notification sound to assist doctors in detection. Also, our technology tackles lesion oversight and blind spots, supporting a thorough examination. The Landmark Photo Checker aids practitioners in efficiently navigating stomach landmarks. This breakthrough in AI technology, displayed on a single endoscopic screen, marks a new era in gastrointestinal endoscopy. With CAD EYE, we envision a comprehensive solution for gastrointestinal endoscopy, contributing to early detection, especially in the Asian Pacific region where gastrointestinal cancer is prevalent. Fujifilm remains committed to the region's comprehensive development, providing innovative solutions and top-quality products, applying science and technology to enhance healthcare services."  

Under its corporate slogan “Value from Innovation” Fujifilm's commitment to advancing the healthcare industry in Asia and globally remains unwavering. This steadfast commitment underscores Fujifilm's proactive role in driving positive change and fostering advancements in healthcare solutions on a global scale.